Skip to main content
. 2014 Sep 18;5(2):459–469. doi: 10.1007/s13300-014-0082-y

Fig. 2.

Fig. 2

Risk of confirmed hypoglycemia as a function of the most recently measured glycated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus after treatment with glimepiride 6 mg/day + metformin (open diamond; n = 589), glimepiride “other” + metformin (dash dotted line; n = 514) or glimepiride 2 mg/day + metformin (dotted line; n = 417). Risks are shown for week 24 [intent-to-treat (ITT) population]